Sugi Predict

Sugi Predict / Compounds / SCHEMBL150915

SCHEMBL150915

SCHEMBL150915

COc1ccc(O)c(C(=O)Cc2ccccc2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.68
▸ RAB9A P51151 6/20 0.68
▸ SMN1; SMN2 Q16637 5/20 0.68
▸ MEN1 O00255 4/20 0.68
▸ KMT2A Q03164 4/20 0.68
▸ HPGD P15428 4/20 0.68
▸ TP53 P04637 3/20 0.68
▸ ALDH1A1 P00352 3/20 0.68
▸ KDM4E B2RXH2 3/20 0.68
▸ MAPT P10636 3/20 0.68
▸ LMNA P02545 3/20 0.68
▸ ALOX12 P18054 2/20 0.68
▸ HSD17B10 Q99714 2/20 0.68
▸ L3MBTL1 Q9Y468 1/20 0.62
▸ USP2 O75604 3/20 0.60
▸ HSP90AA1 P07900 1/20 0.58
▸ CYP3A4 P08684 2/20 0.57
▸ ATM Q13315 1/20 0.57
▸ TSHR P16473 3/20 0.53
▸ ALOX15 P16050 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29586454 1.00 NPC1 (0.68) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL17637551 0.90 NPC1 (0.58) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL29586539 0.88 NPC1 (0.74) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL3811897 0.88 NPC1 (0.74) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL28589540 0.85 USP2 (0.73) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL4838604 0.85 USP2 (0.73) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL6473953 0.85 SMN1; SMN2 (0.78) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL17637149 0.85 HSD11B1 (0.63) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL28569171 0.84 USP2 (0.58) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL9061935 0.82 ESR1 (0.59) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 — — US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 — — EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP disclosed
US-9655880-B2 Azetidine estrogen receptor modulators and uses thereof GENENTECH, INC. (US) 2017-05-23 — — US disclosed
US-20160367526-A1 AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF GENENTECH, INC. (US) 2016-12-22 — — US disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 — — US disclosed
US-9475798-B2 Azetidine estrogen receptor modulators and uses thereof GENENTECH, INC. (US) 2016-10-25 — — US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 — — US disclosed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 — — EP disclosed
US-20160175284-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF GENENTECH, INC. (US) 2016-06-23 — — US disclosed
US-20160090377-A1 AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF GENENTECH, INC. (US) 2016-03-31 — — US disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 — — US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 NPC1 1387/4885RAB9A 1413/4885SMN1; SMN2 2558/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NPC1 1419/4885RAB9A 1297/4885SMN1; SMN2 2637/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NPC1 1419/4885RAB9A 1297/4885SMN1; SMN2 2637/4885
US-20160090377-A1 AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ESR1, ESR2, GPER1 NPC1 1043/4885RAB9A 1163/4885SMN1; SMN2 4543/4885
US-20160367526-A1 AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ESR1, ESR2, GPER1 NPC1 1043/4885RAB9A 1163/4885SMN1; SMN2 4543/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NPC1 1419/4885RAB9A 1297/4885SMN1; SMN2 2637/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NPC1 1419/4885RAB9A 1297/4885SMN1; SMN2 2637/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A NPC1 2061/4885RAB9A 1518/4885SMN1; SMN2 2484/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NPC1 1419/4885RAB9A 1297/4885SMN1; SMN2 2637/4885
US-20160175284-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ESR2, GPER1, ESR1 NPC1 1794/4885RAB9A 3980/4885SMN1; SMN2 4496/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NPC1 1419/4885RAB9A 1297/4885SMN1; SMN2 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.